Category: pharma & healthcare

Topline data from the SELECT trial look good. But this may not necessarily change payer coverage policies on weight loss agents, at least not in the short term.

Applying Swift’s blueprint to healthcare starts with frankly and directly acknowledging to patients the loss of autonomy and how this habitually hamstrings doctors.

The Klotho gene has gained increasing attention for its anti-aging properties. A new study finds that the benefits of this circulating hormone extend beyond the brain.

For certain drugs Medicare selects for price negotiation it may be difficult to achieve deeper discounts than the rebates these pharmaceuticals currently face.

New artificial implant scaffolding methods may be the next great leap in bone healing medicine.

In Clinical Ophthalmology, a review examined the investigational therapeutics for treating dry age-related macular degeneration, including protein-based therapies.

There’s certainly plenty of demand for and hype around the new wave of weight loss agents. But insurers are pulling back on coverage of these products.

There’s certainly plenty of demand for and hype around the new wave of weight loss agents. But insurers are pulling back on coverage of these products.

As CMS expands coverage of Leqembi it’s unclear how patient registries will work, how comprehensive scan coverage will be, and whether local carriers have any discretion.

Gene therapy is currently one of the trailblazing treatments for dry age-related macular degeneration under research.